Saudi Arabia, UAE or Kuwait: Which Gulf Market Should a Medical Device Manufacturer Enter First?

"We want to enter the GCC." It is the sentence that starts most first conversations with an international manufacturer, and it hides the real decision. The Gulf is six countries with six regulators, six procurement systems, and very different sizes. Entering all of them at once spreads a limited budget thinly and produces registrations nobody is selling behind. The practical question is which market to enter first, and the answer depends on three things: where the demand for your product is, how each regulator treats it, and what the local partner requirement means for your control.

This article compares the three markets manufacturers most often weigh against each other: Saudi Arabia, the United Arab Emirates, and Kuwait.

1. Three questions that decide the sequence

Where is the volume? Saudi Arabia is the largest healthcare market in the region by a wide margin, with the majority of spending coming from the public sector. The UAE is smaller but wealthier per capita, with a large private sector and a strong position as a regional commercial hub. Kuwait is smaller again, with a public system that dominates provision and buys centrally.

How does the regulator treat your product? All three run risk-based classification and require a local representative for foreign manufacturers, but the systems differ in structure, in what they accept from your existing approvals, and in how the local representative's role is defined.

What does the partner requirement mean for control? In every market the marketing authorization is applied for and held through a local representative. How you structure that relationship in your first market sets the pattern for the others.

2. Saudi Arabia

Regulator and authorization. The Saudi Food & Drug Authority (SFDA) issues a Medical Device Marketing Authorization (MDMA) through its GHAD electronic system. Devices are classified A to D. The MDMA is valid for three years.

Local representative. A Saudi-resident Authorized Representative holding an SFDA AR licence is mandatory for foreign manufacturers. The AR need not be your distributor.

Existing approvals. Prior approval in a reference country is not a formal prerequisite, but existing approvals (CE, FDA, and others) are requested and materially shorten technical review.

Procurement. Multiple institutional channels: Ministry of Health hospitals and clusters through NUPCO; specialist institutions, National Guard Health Affairs, and military medical services through their own procurement; and a growing private sector. Local content preference applies in public procurement.

Best first market when: volume matters; the product addresses institutional demand; or the manufacturer intends to build a lasting regional presence. Saudi Arabia is where most of the Gulf's patients, hospitals, and public budget are.

3. United Arab Emirates

Regulator and authorization. Medical device registration is federal. Under Federal Decree-Law No. 38 of 2024 the Emirates Drug Establishment (EDE) has taken over the regulatory services previously handled by the Ministry of Health and Prevention (MOHAP), and it now issues the marketing authorization for medical devices. Devices are classified in four risk classes. The Dubai Health Authority and the Department of Health Abu Dhabi license healthcare facilities and professionals in their emirates; they do not run separate device registries, although they may ask for proof of federal registration during procurement or inspection.

Local representative. A UAE-licensed local authorized representative, acting as marketing authorization holder, is required for foreign manufacturers. It submits the application and manages post-market obligations.

Existing approvals. Not a substitute for federal registration; supporting approvals strengthen the file.

Procurement. A mix of government providers by emirate, a large and sophisticated private hospital sector, and a well-developed distribution and free-zone logistics base that many manufacturers use as a regional hub.

Best first market when: the product is private-sector or consumer-led (aesthetics, wellness, premium diagnostics, digital health); the manufacturer wants a regional office and logistics base; or the immediate goal is visibility across the GCC through Dubai's commercial and exhibition platforms.

4. Kuwait

Regulator and authorization. The Ministry of Health, through its drug and food control administration, registers medical devices under Ministerial Decree 13 of 2022, which classifies devices into four categories with requirements commensurate with risk. Registration documentation covers administrative information, device information and labelling, a declaration of conformity, and summary technical documentation, with additional requirements for higher-risk classes.

Local representative. Registration documentation is prepared in relation to the local agent as well as the manufacturer; in practice foreign manufacturers work through a Kuwaiti company.

Existing approvals. Supporting documentation from existing approvals is expected as part of the technical file.

Procurement. The public system dominates provision, and public purchasing is largely centralised through the Ministry of Health. A single well-placed local partner with Ministry access matters more here than in either of the larger markets.

Best first market when: the manufacturer already has a strong Kuwaiti partner; the product is specialised and suits a small number of centralised buyers; or a Kuwait registration is a stepping stone within an existing GCC relationship.

5. Side by side

6. Three common sequences

Saudi first. The default for institutional products and for manufacturers serious about the region. Registration and partner structure are the most demanding, and the payoff is the largest. A Saudi MDMA is well regarded across the Gulf and is often the first thing a UAE or Kuwaiti distributor asks about.

UAE first, Saudi second. Common for private-sector products and for companies that want a regional base. The UAE registration and a Dubai office establish presence and relationships; Saudi registration follows once demand is confirmed. The risk is treating UAE success as evidence of Saudi demand; the markets differ.

Kuwait alongside Saudi. For manufacturers with a strong Kuwaiti partner or a specialised product, Kuwait can run in parallel with Saudi Arabia at modest additional cost, because the technical file is largely the same and the buyer landscape is compact.

What rarely works is registering everywhere at once with no partner in place in any market. Each authorization costs money and time to obtain and maintain; a registration with no commercial plan behind it is an expense, not an asset.

Frequently asked questions

Is there a single GCC registration?

No. Each country registers separately. Regional harmonisation initiatives exist, but a marketing authorization is national.

Can one distributor cover all three markets?

Some regional groups operate in several Gulf countries. Even then, registration and licensing are national, and performance should be measured market by market.

Does a Saudi MDMA speed up registration elsewhere?

It does not replace another country's process, but the same technical file, with existing approvals and Arabic labelling already prepared, makes subsequent applications faster and cheaper.

Which market is fastest to register in?

It depends on class and file quality more than on country. Plan on several months in any of the three for a well-prepared file, and longer for high-risk devices.

Related reading: SFDA Registration (MDMA) · How to Choose a Saudi Distributor · Beyond NUPCO

This article summarises published regulatory frameworks as of the date above for general guidance. Requirements, fees, and timelines change; confirm current details with each regulator or a licensed local representative before acting.